Table 1.
Induction regimen | Number of patients, n = 816 |
---|---|
IMiD | 489 (59.9%) |
Lenalidomide dexamethasone | 382 |
Lenalidomide, cyclophosphamide, dexamethasone | 38 |
Thalidomide, melphalan, prednisone | 21 |
Lenalidomide, melphalan, prednisone | 20 |
Thalidomide dexamethasone | 20 |
Lenalidomide | 6 |
Pomalidomide dexamethasone | 1 |
Lenalidomide bendamustine | 1 |
PI | 185 (22.6%) |
Bortezomib, cyclophosphamide, dexamethasone | 110 |
Bortezomib dexamethasone | 63 |
Bortezomib, doxorubicin, dexamethasone | 4 |
Bortezomib, melphalan, prednisone | 3 |
Bortezomib | 2 |
Ixazomib, cyclophosphamide, dexamethasone | 2 |
Bortezomib, cyclophosphamide, prednisone | 1 |
IMiD and PI | 80 (9.8%) |
Bortezomib, lenalidomide, dexamethasone | 59 |
Bortezomib, thalidomide, dexamethasone | 8 |
Carfilzomib, thalidomide, cyclophosphamide, dexamethasone | 5 |
VDT-PACE | 3 |
Ixazomib, lenalidomide, dexamethasone | 3 |
Bortezomib, lenalidomide, cyclophosphamide, dexamethasone | 1 |
Carfilzomib, lenalidomide, cyclophosphamide, dexamethasone | 1 |
No novel agent | 62 (7.6%) |
Dexamethasone | 31 |
Melphalan prednisone | 26 |
Melphalan dexamethasone | 2 |
Cyclophosphamide prednisone | 1 |
Cyclophosphamide dexamethasone | 1 |
Prednisone | 1 |
IMiD indicates immunomodulatory drug; PI, proteosome inhibitor; and VDT-PACE, bortezomib, dexamethasone, lenalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide